3160 PORTER DR., PALO ALTO, CA
Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches
Director Resignation - Dr. Randal W. Scott Steps Down from Board
FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
Submits NDA to FDA for Encaleret for Individuals Living with ADH1
News
Reports First Quarter 2026 Financial Results and Corporate Updates
Annual Report to Security Holders
Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates
Q1
FY 2024
Q3
Q2
FY 2023
S-3ASR
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Confidential Treatment Order